Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving.

AIM

To identify the clinical and economic circumstances under which a pharmacogenomic test that predicts response to inhaled corticosteroids might be a cost-effective option for individuals with asthma.

MATERIALS & METHODS

We synthesized published data on clinical and economic outcomes to project 10-year costs, quality-adjusted life-years and cost-effectiveness of pharmacogenomic testing for inhaled corticosteroid response. We assumed the pharmacogenomic test cost was $500 with a sensitivity and specificity of 84 and 98%, respectively. These were varied in sensitivity analyses.

RESULTS

Both strategies, pharmacogenomic testing for inhaled corticosteroid response and no testing conferred 7.1 quality-adjusted life-years. Compared with no testing, pharmacogenomic testing costs less.

CONCLUSION

Pharmacogenomic testing for asthma is cost-saving and noninferior in improving health. Original submitted 19 November 2014; Revision submitted 23 February 2015.

Investigators
Abbreviation
Pharmacogenomics
Publication Date
2015-04-16
Volume
16
Issue
6
Page Numbers
591-600
Pubmed ID
25880024
Medium
Print-Electronic
Full Title
Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving.
Authors
Wu AC, Gay C, Rett MD, Stout N, Weiss ST, Fuhlbrigge AL